ArticleCureus2024

Comparison of Efficacy, Safety, and Economic Outcomes Between Biosimilar ABP 215 and Originator Bevacizumab in Japanese Patients With Colorectal Cancer.

Takahiro Sumimoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.